US-licensed Xolair

BIOLOGICAL2 trials

Sponsors

Celltrion, Kashiv BioSciences, LLC

Conditions

Healthy

Phase 1

To Compare the PK and Safety of Omalizumab (CT-P39, EU-approved Xolair, and US-licensed Xolair) in Healthy Subjects

CompletedNCT04018313

CelltrionHealthy

Start: 2020-05-28End: 2021-04-30Updated: 2023-05-11

To Compare the PK, PD, Safety & Immunogenicity of ADL-018 in Healthy Subjects

CompletedNCT05413161

Kashiv BioSciences, LLCHealthy

Start: 2022-07-07End: 2023-06-30Updated: 2023-07-03

Related Papers

Pharmacokinetic equivalence of CT‐P39 and reference omalizumab in healthy individuals: A randomised, double‐blind, parallel‐group, Phase 1 trial

Clinical and Translational Allergy2022-11-0112 citations